GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)		6 Months Ended	9 Months Ended
	Dec. 17, 2013 USD ($) project $ / shares shares	Sep. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	May 17, 2016 EUR (€)	May 17, 2016 USD ($)	Jan. 01, 2015 EUR (€)	Oct. 31, 2013 $ / shares
Indefinite-lived Intangible Assets [Line Items]
Goodwill		$ 2,722,985	$ 2,722,985
Goodwill impairment		0	0
Number of independent research projects | project	2
Impairment charge		$ 0	$ 0
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Price per share (in dollars per share) | $ / shares	$ 0.13
Shares issued (in dollars per share) | $ / shares	$ 0.28						$ 0.13
Indefinite-lived intangible asset acquired	$ 1,300,000
IPR&D | Eurema Consulting S.r.l.
Indefinite-lived Intangible Assets [Line Items]
Stock issued (in shares) | shares	5,000,000
IPR&D | TES Pharma S.r.l.
Indefinite-lived Intangible Assets [Line Items]
Stock issued (in shares) | shares	5,000,000
Clinical Research Organization | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs | €						€ 100,002
Amended License Agreement | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs | €				€ 435,000
Rasna, Inc.
Indefinite-lived Intangible Assets [Line Items]
Goodwill					$ 2,722,985
Rasna, Inc. | Intellectual property
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs					236,269
Rasna, Inc. | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs					$ 613,100